anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Type 2 diabetes is associated with damage, dysfunction, and failure of various organs. The coexistence of diabetes and hypertension is particularly damaging to cardiac and peripheral vascular structure and function. These diseases, either alone or combined, result in increased left ventricular mass and wall thickness, left ventricular diastolic dysfunction, impaired endothelial vasodilator function, and increased vascular stiffness. Although several health organizations endorse exercise training as a therapeutic modality for type 2 diabetes, most studies of exercise and diabetes have focused on glycemic control but not on cardiovascular health. Although exercise lowers blood pressure in persons without diabetes, there are profound gaps in knowledge about the effects of exercise training on blood pressure and cardiovascular health in persons with type 2 diabetes. The primary specific aim of this study is to determine if exercise training reduces blood pressure in persons who have both type 2 diabetes and high normal blood pressure or mild hypertension prehypertension or Stage 1 (mild) hypertension. Subjects will be randomized to 6-months of exercise training, consistent with established guidelines for diabetes and for hypertension, or to a usual care control group. The second specific aim is to identify the effects of exercise training on parameters of cardiac and peripheral vascular structure and function related to cardiovascular disease in diabetes and hypertension. We will assess left ventricular mass, left ventricular diastolic function, endothelial vasodilator function, and vascular stiffness using high-resolution ultrasound, Doppler echocardiography, and magnetic resonance imaging. We will also examine interleukin-6 and high-resolution C-reactive protein as novel risk factors for cardiovascular disease and diabetes to determine the effects of exercise training on the inflammatory process. Because exercise training improves fitness and may improve body composition and regional fat distribution, the associations of change in these parameters with change in blood pressure and cardiac and peripheral vascular structure and function will be analyzed. An equal number of men and women will be enrolled, and a third specific aim of the study is to examine gender differences in response to exercise training. This study will expand the scientific knowledge that defines exercise guidelines and will provide new insight into the mechanisms by which exercise reduces blood pressure and improves cardiovascular health in persons with type 2 diabetes and hypertension.
A small-molecule Stat3 dimerization inhibitor, S3I-M2001. is described and the dynamics of intracellular processing of activated Stat3 within the context of the biochemical and biological effects of the Stat3 chemical probe inhibitor are elucidated. S3I-M2001 is a newly-identified oxazole-based peptidomimetic of the Stat3 Src Homology (SH) 2 domain-binding phosphotyrosine peptide that selectively disrupts active Stat3:Stat3 dimers. Stat3-dependent malignant transformation, survival, and migration and invasion of mouse and human cancer cells harboring persistently-activated Stat3 were inhibited by S3I-M2001. S3I-M2001 inhibited Stat3-dependent transcriptional regulation of tumor survival genes, such as Bcl-xL. The disclosed compound is useful as a new potential treatment for certain cancers.
Here, we explored the role of Prolyl 4-Hydroxylase Subunit Alpha 3 (P4HA3), the most recently identified member of the prolyl-4-hydroxylase (P4H) family, in head and neck squamous cell carcinoma (HNSCC) progression. P4HA3 is upregulated during cancer progression; however, its specific role in HNSCC progression remains elusive. Thus, this study aimed to elucidate the regulatory function of P4HA3 in HNSCC development and progression and to describe the underlying mechanisms. Initially, we analyzed the correlation between the expression of P4HA3 and the WNT pathway genes and clinicopathologic features in HNSCC based on microarray data from The Cancer Genome Atlas (TCGA). Next, we used Gene Oncology (GO) functional data to describe several potentially associated pathways in HNSCC. Then, we knocked down P4HA3 in SCC15 and SCC25 cells, two classic HNSCC cell lines, and assessed the resulting changes using RT-qPCR. Furthermore, we used Western blot to evaluate the regulatory role of P4HA3 in the epithelial-to-mesenchymal transition (EMT) and the WNT/β-catenin signaling pathway. To explore the effect of P4HA3 knockdown on tumor progression, in vivo experiments were conducted using a murine model. Immunohistochemistry assays were then employed to identify proteins associated with EMT and the WNT/β-catenin signaling pathway in tumor tissues. Upregulated P4HA3 in HNSCC patient tumor tissues was positively correlated with poor prognosis. Notably, P4HA3 knockdown significantly inhibited the proliferative and invasive abilities of HNSCC. The levels of genes and proteins associated with EMT and the WNT/β-catenin signaling pathway were also markedly reduced by P4HA3 knockdown. Importantly, the in vivo experiments demonstrated that P4HA3 can promote subcutaneous tumorigenesis in nude mice and knockdown of P4HA3 induce a significant ihibitation of EMT and WNT/β-catenin pathway detected by immunohistochemistry assay in tumor tissues. In summary, we demonstrated that P4HA3 is a promising diagnostic and therapeutic biomarker for HNSCC. As an oncogene, P4HA3 increases HNSCC proliferation by inducing the EMT and activating the WNT/β-catenin signaling pathway.
It will consist of 36 patients diagnosed with ILD. The patients whose demographic information such as age, height and weight will be questioned will then be evaluated with a desktop spirometer, peripheral muscle strength measurement with a digital myometer, and functional capacity with a 6MWT. The Moxy device, which is a NIRS, will be attached to the upper leg (the vastus lateralis of the quadriceps muscle) and the rib (intercostal muscles) with a silk patch, and the oxygenation of the muscles here will be measured during the 6MWT. In addition, fatigue status will be evaluated with the Modified Borg Scale.
RVA Breathes includes family-based asthma self-management education (delivered by Community Health Workers \[CHWs\] with the Institute for Public Health Innovation), home environmental remediation (with Richmond City Health Department's Healthy Homes Initiative), and a school nurse component (with elementary schools in the Richmond City Public School System). These interventions capitalize among existing resources and relationships with stakeholders in Richmond, each of which is committed to RVA Breathes. Two hundred-fifty children with asthma and their caregivers participated in a randomized clinical trial of RVA Breathes. After completing a baseline assessment, families were randomized to one of three conditions: 1) asthma education + home remediation + school intervention, 2) asthma education + home remediation and 3) comparator condition (Enhanced Standard of Care, E-SOC). Families participated in the program for 9 months and completed follow-up assessments (post-treatment and 3-, 6-, and 9-month) to measure changes in healthcare utilization and the impact of the program on child asthma outcomes. Conditions were compared on the primary outcome of asthma-related healthcare utilization, including asthma specific ED visits and hospital admissions. Secondary outcomes included need for controller medication use, asthma control, asthma symptoms, asthma action plans, and quality of life. We will also evaluate the sustainability of RVA Breathes after 9 months (without active intervention), including a review of qualitative data from participants and stakeholders in the program. Findings from this trial will allow for dissemination and implementation of RVA Breathes as a sustainable program in the Richmond are.
The subject matter described herein includes methods, systems, and computer program products for biological inventory tracking using cloud services and mobile devices. According to one method, information is input from a mobile device about a specimen sample. The information includes an image of the specimen sample captured using the mobile device including an identifying indicia. The information is uploaded and stored in an encrypted format accessible to authorized and verified users. At least one characteristic of the specimen sample is determined based on the information. Tracking and status information, as well as notifications or reminders, regarding the specimen sample are provided in real-time or near real-time to the mobile device.
A variety of different types of nasal vaccine systems have been described including cholera toxin, microspheres, nanoparticles, liposomes, attenuated virus, and outer membrane proteins (proteosomes). The present invention is directed toward a novel nasal vaccine composition that utilizes the cationic polysaccharide, chitosan, as a delivery system. Chitosan is a polysaccharide comprising copolymers of glucosamine and N-acetylglucosamine. The term chitosan encompasses a series of chitosan polymers with different molecular weights (50 kDa-2,000 kDa) and degree of acetylation (40%-98%). Several vaccine animal studies were carried out employing influenza or pertussis antigens in combination with chitosan. Nasal administration of chitosan-antigen nasal vaccines induced significant serum IgG responses and secretory IgA levels. Animals vaccinated via the nasal route with various chitosan-antigen vaccines were also found to be protected against the appropriate challenge.
PURPOSE: To obtain a curing agent having excellent curing properties for a hypersensitive intestine syndrome or another inflammatory intestine disease or chronic diarrhea, etc., of a mammal and administrable by a systemic administration in oral or parenteral administration, etc., or by a suppository, etc., comprising an angiotensin conversing enzyme depressor. CONSTITUTION: This curing agent is composed of an angiotensin conversing enzyme(ACE) depressor, e.g. a phosphonate-substituted amino or imino acid such as ceranapril or their salt, a substituted proline derivative such as captopril, a carboxyalkyl dipeptide derivative such as enalapril, a phosphinylalkanoylproline derivative, etc., such as phosinopril. A carrier and an auxiliary are added to the suppressor and formulated to a tablet, an injection, etc., or an enema or a suppository, etc., then administrated to a mammal. The dose of the depressor is 0.01-100mg/kg/day and administrated by dividing to 1-4 times. The agent is useful for Crohn disease, colitis, chronic diarrhea, diabetes, gastrointestinal injury, etc.
The invention discloses an exosome, a preparation method of the exosome and application of the exosome in preparation of a medicament for treating skin superficial tumors. Specifically, the method comprises the steps of carrying out Trail gene transformation on escherichia coli to express Trail protein, extracting an exosome of the Trail protein, treating lysozyme, modifying nanoparticles with targeting peptide, and loading a photosensitizer indocyanine green ICG. After transdermal administration, the nanoparticle is triggered by near infrared light to generate heat by ICG and release singlet oxygen, and the singlet oxygen and the Trail protein cooperate to kill tumor cells. The preparation method of the exosome overcomes the defects of the traditional method, and has the advantages of high yield, short period, low cost, simple and convenient medicine loading, high medicine loading rate and the like. At present, no report that the exosome is applied to transdermal administration exists, and the exosome can be efficiently subjected to transdermal penetration and provides a new strategy for treating skin diseases. In addition, no therapy for curing the melanoma exists clinically, and after the exosome is subjected to transdermal penetration, the exosome can be combined with photo-thermal therapy and biological therapy to synergistically inhibit the development and metastasis of the melanoma, so that the exosome has a good in-vivo treatment effect.
Electroconvulsive therapy (ECT) is an extremely important therapeutic method in the treatment of certain psychiatric conditions. Its' effect has been demonstrated in many clinical trials, and the indications for the use of ECT are clearly defined. Thus, the absolute indications for the use of ECT are catatonia and malignant neuroleptic syndrome, while the relative indications for ECT are therapy-resistant schizophrenia, depression and chronic suicidality. When the lead psychiatrist sets an indication for the use of ECT, pre-ECT evaluation is conducted. Although the pre-evaluation aims to assess the psychophysical condition of the patient and to determine the potential risks and possible side effects of such therapy, no clear algorithm of procedures is specified. There is no data on clear guidelines for the necessary processing prior to the application of ECT, both at national levels and globally. The assessment recommendations, however, are very broad, and most of them are focused on the ethical issues of applying ECT. The standardized pre-ECT evaluation would provide physicians and patients a systematic and evidence-based risk assessment and presumption of adverse reaction profiles.
The invention discloses an antineoplastic protein extract in Ramaria botrytis, and a preparation method and application thereof. The preparation method comprises the following steps: pulverizing Ramaria botrytis sporophores into powder, leaching, salting out, dialyzing, freeze-drying, carrying out ion exchange, and carrying out gel chromatography to obtain the antineoplastic protein extract. The protein extract is a monomer protein with the molecular weight of 18.5kDa, the amino acid sequence has 69% of degree of similarity to ubiquitin protein p19848 of Coprinellus Congregatus, and thus, the protein extract is a ubiquitin-like protein. The antineoplastic protein extract has an obvious inhibiting action on the growth of the human lung adenocarcinoma cell strain A549. The Ramaria botrytis antineoplastic protein extract is a natural extract, and is harmless to the human and environment. The preparation method is simple, is low in cost, and is suitable for industrial production.
Vital signs (VSs) will be measured, electrocardiograms (ECGs) will be acquired, and blood will be sent to the clinical laboratory for safety assessments before a single dose, intravenous (IV) administration of 555 MBq of Carbon-11 butanol. VSs will be re-measured, ECGs will be acquired again, and more blood will be sent to the clinical laboratory for repeat safety assessments after 2 hours of whole body (WB) scanning. WB scanning will consist of imaging acquisition sweeps of 200 cm from head-to-toe over 180 secs (3 min). Up to 40 sweeps per imaging session will be performed. The subjects will then be given a rest period ("coffee break") for about two hours, after which the entire sequence of events will be repeated. The primary outcome measure will be related to radiation safety derived from the areas under the time-activity curves (AUCs) for internal organs. Co-primary clinical safety measures will include changes in VSs, ECG parameters such as the PR and corrected QT intervals, and clinical laboratory tests, such as proteins that reflect renal and hepatic function. Secondary endpoints will include the time-activity curves (TACs) and total volumes of distribution (VT) in several brain regions. The results should allow calculation of the repeatability coefficients (RCs) under zero-biological-change conditions. RC values will be essential for understanding whether future measurements of effect sizes in response to therapeutic maneuvers or the differences between groups are meaningful.
The invention relates to a medicine and a making method that is a walnut ginger pilular, which is characterized in that the making method is: the preparation of medical ointment comprising materials, pretreatment and making medical ointment; the making of pharmacy pilular comprising heating up, mixing and making pilular. The walnut ginger pilular is a medicine taking the walnut pome and the ginger as material and matching with white honey. The appearance of the product presents yellow fraction, the shape of pharmacy pilular, and the taste is fragrant and sweet. The pilular is used for the oldness with chronic cough and no prostrating or the disorder of short breath and difficult prostrating. Cough and asthma can be relieved by taking 1 pilular before sleeping every night. The pilular has the advantages of relieving a cough and asthma.
<P>PROBLEM TO BE SOLVED: To provide a skin cosmetic good in feeling in use through sustainedly suppressing sebum-related stickiness while having refreshing cool feeling, and excellent in skin-brightening effect.  <P>SOLUTION: The skin cosmetic comprises water-absorbed porous powder and also contains a skin-brightening agent, wherein the surface of the porous powder is coated with a caking agent. Particularly, the porous powder consists of e.g. flaky porous silica, spherical porous silica, silicone-treated particulate zinc oxide, methyl methacrylate cross polymer, amorphous particulate silicic anhydride, and the caking agent comprises an oil component which contains a crosslinked organopolysiloxane. In this skin cosmetic, the water-absorbing ability of the whole powder is 50-150 mL/100g.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds. Participants will be in the scanner for 60 minutes for 5 days. This will be used as the control condition and compared with TI-NDBS and tDCS.
All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects.
Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
The invention discloses an external preparation for relieving itching due to mosquito bite and miliaria, belonging to the technical field of an external preparation. The preparation comprises radix zanthoxyli extract which is good in itching reliving effect, without grease and stimulation feeling. The preparation has multiple dosage forms. Experiment results are confirmed that after being bitten by mosquitoes, more than 90% of people have itching relieving effect within five minutes after using the external preparation, and biting bubbles can be removed within 2 hours. The test also confirms that more early the external preparation is used, the better the effect is after being bitten by mosquitoes. People does not scratch skin after itching is fast relieved, so that the bitten scar cannot be left on the skin due to no scratch.
A 63-yr-old woman with end-stage CKD secondary to glomerulonephritis, on hemodialysis therapy, presented with scoliosis, back pain, and progressive loss of physical function for which corrective surgery was planned. Optimization of bone health was requested by the surgeon as a DXA scan had revealed osteoporosis at spine, hip, and forearm. Due to previous subtotal parathyroidectomy and normal parathyroid hormone and bone-specific alkaline phosphatase levels, a low bone turnover state was suspected. An iliac bone biopsy was performed and revealed low bone turnover, a mineralization defect, and severe osteoporosis. The patient was treated with calcium and intensified vitamin D supplementation, followed by a 2-yr course of teriparatide. Monitoring of bone turnover markers indicated a bone anabolic response to therapy, and a repeat DXA showed increases in BMD at spine and hip. A repeat biopsy at end of treatment showed normal bone turnover and mineralization. This case demonstrates the complicated bone health of patients with advanced CKD. As there are no randomized trials for fracture pretention in patients with CKD, care must be individualized and is often based on expert opinion. The use of bone biopsy is safe and informative in guiding therapy.
INTRODUCTION: Balance assessments are an important component of rehabilitation. Considering the increasing use of telemedicine to meet rehabilitation needs, it is important to examine the feasibility of such assessments. This study aimed to examine the reliability and validity of the Tinetti Performance-Oriented Mobility Assessment Balance Subscale (POMA-B) when applied via synchronous and asynchronous tele-assessment.
METHODS: Twenty-five patients with chronic stroke were included in the study. The first physiotherapist assessed the patients on the first day in a face-to-face clinical setting. Synchronous or asynchronous tele-assessment was applied the next day. The assessments were performed in the same time zone, with an interval of one day. The synchronous tele-assessment was done online in real time by the first and second physiotherapists. A reference assessment video was sent to the patients for asynchronous tele-assessment. They were asked to make a video recording while performing the evaluation activities according to the reference video. Then the first and second physiotherapists assessed these video recordings separately. All the tests were repeated 10 days later to determine the intra-rater reliability of the tele-assessment methods.
RESULTS: The intra-class correlation coefficients ranged from 0.96 to 0.98 for inter-rater reliability and from 0.97 to 0.98 for intra-rater reliability for both tele-assessment methods. Both asynchronous and asynchronous tele-assessment methods were medium correlated with the face-to-face versions.
CONCLUSIONS: We demonstrated the validity and reliability of the POMA-B in chronic stroke patients with different tele-assessment methods, typically using the internet and available devices.
Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
PURPOSE: A composition containing citreorosein for preventing and treating metabolic syndrome is provided to ensure stable treatment effect without side effects and to be used as a pharmaceutical composition and a health food composition. CONSTITUTION: A composition for preventing or treating metabolic syndrome contains citreorosein. The metabolic syndrome is selected from the group consisting of hypertriglyceridemia, obesity, hypertension, arteriosclerosis, hyperlipidemia, liver diseases, hyperinsulinemia, hyperglycermia, diabetes, and insulin resistance disorder. The diabetes is type 2 diabetes. Citreorosein activates LKB1 (liver kinase B1) and increases glucose uptake in a cell by activated AMPK (AMP-activated protein kinase). A pharmaceutical composition for preventing or treating metabolic syndrome contains citreorosein. A health food composition for preventing or treating metabolic syndrome contains citreorosein.